Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

BioStock Investor Meeting: WntResearch presents

It has been an eventful quarter for WntResearch that develops the drug candidate Foxy-5 for the treatment of colon cancer. The company is currently conducting the phase IIb study NeoFox from which the company recently announced promising findings, causing a rally in the stock. The company's CEO Pernilla Sandwall attended BioStock Investor Meeting and told us more about both the company and the new findings.Read the full article at biostock.se:https://www.biostock.se/en/2022/09/biostock-investor-meeting-wntresearch-presents/This is a press release from BioStock - Connecting Innovation &

Clinical Laserthermia Systems receives FDA 510(k) clearance for its MR guided laser ablation system in neurosurgery and initiates commercialization

Lund, Sverige – Clinical Laserthermia Systems AB (publ) (CLS) today announced that its second generation TRANBERG® Thermal Therapy System with Thermoguide™ Workstation has received 510(k) clearance from the US Food and Drug Administration (FDA). The clearance marks a breakthrough in the field of neurosurgery and for minimally invasive treatments of brain lesions that will now be performed more efficiently and safely. The system will be commercialized by CLS’s global distributor ClearPoint Neuro, Inc (Nasdaq:CLPT).CLS’s 510(k) clearance was achieved thanks to a close collaboration with CLS’s

Karlatornet in Gothenburg– now tallest in Scandinavia

Karlatornet has now reached 60 floors and even though there are 13 floors left to the full height, the building is already the tallest, not only in Sweden but also in the whole of Scandinavia. While Karlatornet is continuing to grow in height, completion of the apartments further down the tower is in progress and occupation will start in just under one year.Earlier this week, the casting was carried out of the 60th floor of Karlatornet’s core and the tower has therefore reached a height of 193 metres. This means that the project has surpassed Turning Torso’s 190 metres and is the de facto

B. Braun orders DrugLog™ for two new installations in Spain

B. Braun Spain orders two complete DrugLog™ systems for installation at Hospital General Universitario Los Arcos and Hospital Provincial de Castellón.B. Braun in Spain orders two complete DrugLog™ systems for installation at two of Spain's leading cancer hospitals, Hospital General Universitario Los Arcos in Murcia and Hospital Provincial de Castellón. B. Braun Spain is a partner of Pharmacolog and acts as the company's distributor in Spain. DrugLog™ is used for verification of finished chemo admixtures after pharmacy preparation and form part of the B. Braun Chemotherapy Ecosystem. B.

NOTE grows with Ferroamp within Greentech

Last year NOTE introduced a partnership with the fast-growing Swedish Greentech company Ferroamp, which develops Energyhubs systems that in an innovative way integrate solar power, energy storage and DC loads into one system with intelligent control and real-time monitoring. NOTE is manufacturing the electronics and complete systems of the Energyhubs. The demand for Ferroamp's product has increased significantly in recent time, the company is now expecting a strong increase in demand where the partnership with NOTE is estimated to reach SEK 120 million in 2023. The manufacturing takes

Cessatech reports successful outcome of pharmacokinetic trial in children of lead candidate

· Clinical trial 0206 investigated the pharmacokinetics of CT001 in children aged 1-17 undergoing elective surgical procedures.  · Primary endpoint was successfully met by obtaining pharmacokinetic data in this age group, showing relevant clinical exposure ranges.  · Secondary objectives of safety, pain assessment, and acceptance of intranasal administration was at an acceptable levelCessatech A/S announces positive topline outcome of its Phase 1 pharmacokinetics trial with CT001 in children, which met the primary endpoint of the trial. The trial was designed as a non-randomised, open-

President of Energy business Sushil Purohit to leave Wärtsilä

Wärtsilä Corporation, Stock exchange release, 23 September 2022 at 09:30 EESTPresident of Energy business Sushil Purohit to leave Wärtsilä Mr Sushil Purohit, President of the Energy business, Executive Vice President and member of the Board of Management has decided to leave Wärtsilä. He has been appointed to a key position outside of the Group and will leave Wärtsilä at latest in the end of February 2023. Wärtsilä has started the process to recruit a successor for Mr Purohit to lead the Energy business. “We would like to thank Mr Purohit for his contributions to Wärtsilä through the

SAS comment regarding Nasdaq Stockholm’s disciplinary committee's decision

Nasdaq Stockholm's disciplinary committee has today decided to impose a fine on SAS as a result of the company's information handling in connection with the outbreak of SAS’ pilot strike on July 4, 2022.The interest in the mediation between SAS and SAS Scandinavia's pilots’ unions was very high from both domestic and international media. In connection with the mediation ending and the start of the strike on July 4, it was important to inform about the strike as quickly as possible in order to minimize the consequences of the strike for SAS’ customers.   SAS published a regulatory

BioStock Investor Meeting: Lipum presents

Biopharmaceutical company Lipum is developing a new biological drug for the treatment of rheumatoid arthritis (RA) and other chronic inflammatory diseases. The next major goal is to initiate a first clinical study with the candidate SOL-116. CEO Einar Pontén attended the BioStock Investor Meeting in Stockholm and told us more about the way forward.See the presentation at biostock.se: https://www.biostock.se/en/2022/09/biostock-investor-meeting-lipum-presents/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Truecaller’s Board has decided to launch a program to repurchase own shares

Earlier this year Truecaller's 2022 AGM authorized Truecaller’s board to decide on one or more occasions during the time until the next AGM on the buyback of B shares in the company. The maximum B shares that may be repurchased corresponds to a maximum of five (5) percent of the total number of shares in the company on the day of the Annual general meeting. Truecaller's board has now decided to launch a buyback program of its own B shares. The purpose of the program is primarily to adapt Truecaller's capital structure to the company's capital needs.Truecaller has commissioned SEB to manage

Investor AB’s Nomination Committee for the 2023 Annual General Meeting

Investor AB’s Nomination Committee for the Annual General Meeting 2023 has been appointed based on the ownership structure as of August 31, 2022. The Nomination Committee consists of:Leif Johansson, Wallenberg FoundationsAnders Oscarsson, AMF Tjänstepension och AMF FonderMagnus Carlsson, SEB FoundationCarina Silberg, AlectaJacob Wallenberg, Chair of the Board of Investor AB Shareholders having appointed members to the Nomination Committee represent approximately 65 percent of the voting rights for all shares of Investor AB. The Annual General Meeting of Investor AB will

Information about Attana's presentation at Redeye Theme: Diagnostics on September 27 at 09.30

On Tuesday, September 27 at 09.30 Attana will participate in Redeye’s event, Theme: Diagnostics, where Attana’s CEO, Teodor Aastrup, will give a 12-minute presentation followed by an 8-minute Q&A.The presentation will begin with a brief description of the company, and then focus on Attana's business how the company's technology can be used within companion diagnostics and to measure the neutralization capacity of e.g., antibodies. Below is the preliminary agenda for the presentation: 1. Attana in short 2. Companion diagnostics 3. Antibody neutralization capacity 4. Summary

Kemppi introduces the new X5 FastMig Pulse

Kemppi launches the X5 FastMig Pulse welding equipment specifically designed for industrial use. The modular welding solution is designed for various applications in different environments.KEMPPI    MEDIA RELEASE    23 SEPTEMBER 2022   9.00 EET Kemppi introduces the new X5 FastMig Pulse Kemppi launches the X5 FastMig Pulse welding equipment specifically designed for industrial use. The modular welding solution is designed for various applications in different environments, meaning the customer can build the assembly that best suits their needs. X5 FastMig Pulse is designed and

Composition of Atria Plc’s Nomination Board

Atria Plc COMPANY ANNOUNCEMENT 23 September 2022 at 9 amComposition of Atria Plc’s Nomination BoardThe following people were elected to Atria Plc’s Nomination Board at the Annual General Meeting:- Juho Anttikoski, Farmer, representative of Itikka Co-operative- Pasi Korhonen, Farmer, representative of Lihakunta- Ola Sandberg, Farmer, representative of Pohjanmaan Liha- Timo Sallinen Director, Equities, representative of Varma Mutual Pension Insurance Company- Seppo Paavola, Agrologist, Expert Member, Chairman of Atria Plc's Board of DirectorsIn its first meeting the Nomination

Ultomiris approved in EU for gMG

23 September 2022 07:00 BST Ultomiris approved in Europe for the treatment of adults with generalised myasthenia gravis First and only long-acting C5 inhibitor has demonstrated early onset and sustained clinical benefit, and may reduce treatment burden with dosing every 8 weeks Improvement in activities of daily living seen across broad range of patients, including those with milder symptoms  Ultomiris (ravulizumab) has been approved in Europe as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-

2023 AGM: Nomination Committee of Castellum AB

At Castellum AB's 2021 Annual General Meeting (AGM) held on 25 March, it was resolved that the Nomination Committee for the AGM shall consist of the Chairman of the Board and a member appointed by each of the four largest ownership-registered or otherwise known shareholders, as per the last trading day of August each year. If such a shareholder should not wish to appoint a member, the fifth largest shareholder should be consulted, and so on.Castellum’s Chairman of the Board has contacted the largest shareholders, and the Nomination Committee now consists of the following members: ·

A fully recyclable, fiber-based foam for protective packaging by Stora Enso

STORA ENSO OYJ PRESS RELEASE 23 September 2022 at 9:00 EESTPlastic packaging materials such as fossil-based foams seem increasingly outdated in a society that is striving to reduce plastic usage and waste and move towards renewable materials. With regulatory bodies now driving a policy towards limiting or banning fossil-based foam materials in packaging, new solutions are needed. Papira[®] by Stora Enso  is a novel lightweight foam made from pulp fibers. The semi-rigid foam has a high cushioning performance and is

Pandox enters into an agreement to sell InterContinental Montreal

Pandox AB (publ) has entered into an agreement to divest InterContinental Montreal in Canada. The sale includes both the hotel property and hotel operations with a total transaction value of approximately MCAD 80, corresponding to approximately MSEK 660. The closing is planned to take place in the first quarter of 2023.   "We are pleased to have signed an agreement to sell InterContinental Montreal, which we have owned since 2007 and have developed in stages since then. The timing is right, the sale price is attractive, and the buyer has a strong local presence in Montreal. With the

Africa Oil Announces Normal Course Issuer Bid – Launch of Share Buyback Program

Not for Distribution to United States News Wire Services or for Dissemination in the United States VANCOUVER, BC, September 23, 2022 /CNW/ - (AOI–TSX, AOI–Nasdaq-Stockholm) – Africa Oil Corp. (“Africa Oil”, “AOC” or the “Company”) is pleased to announce that the Toronto Stock Exchange (the “TSX”) has approved the Company’s proposed normal course issuer bid (referred to as a share buy-back program in Europe) of up to CAD 95 million (the “NCIB”).   Pursuant to the NCIB, Africa Oil is authorized to repurchase through the facilities of the TSX, Nasdaq Stockholm and/or alternative

Krister Karlsson new COO at SBB

Krister Karlsson has been appointed as the new chief operating officer, COO, at Samhällsbyggnadsbolaget in Norden AB (publ) ("SBB"). Krister succeeds Oscar Lekander, who is leaving the management team and who will continue to work on completing transactions and special projects. Krister Karlsson is today Head of Property Development. Previously, Krister was Head of Planning and Property Development at Rikshem AB and Regional Manager Baltics, Project Manager Sweden and Property Developer at NCC.

Cloudberry Clean Energy ASA | EX. REPAIR OFFERING TODAY

CLOUD – EX. REPAIR OFFERING TODAYIssuer name: Cloudberry Clean Energy ASAEx. date: 23 September 2022Type of corporate action: Repair IssueThis information is published in accordance with the requirements of the Oslo Rule Book II – Issuer Rules. For further information, please contact:Anders Lenborg, CEO, +47 934 13 130, al@cloudberry.noChristian Helland, CVO, +47 418 80 000, ch@cloudberry.noOle-Kristofer Bragnes, Senior Financial Officer, +47 917 03 415, okb@cloudberry.no About CloudberryCloudberry is a renewable energy company operating in the Nordics and in accordance

Oncopeptides provides an update from the meeting with FDAs advisory committee ODAC

STOCKHOLM — September 23, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the Oncologic Drugs Advisory Committee (ODAC), of the US Food and Drug Administration (FDA), has finalized the discussion on the benefit-risk profile of Pepaxto[®] (melphalan flufenamide, also called melflufen). A majority of the panel considered that OCEAN did not confirm a favorable benefit-risk profile in the current indicated patient population. Pepaxto is indicated in

Norsk Solar experiences continued growth in key markets and secures 1.8 MW rooftop solar project in Vietnam

Stavanger, Norway/Ho Chi Minh City, Vietnam, 23 September 2022: Norsk Solar AS (“Norsk Solar”, OSEBX ticker: NSOL), an independent solar power producer focused on commercial and industrial (C&I) projects in emerging markets, has entered into a long-term power purchase agreement (“PPA”) with Lineage Logistics, one of the world’s leading and most innovative temperature-controlled industrial REIT and logistics solutions providers. The PPA is signed by Norsk Solar Vietnam, which is owned by Nordic Impact Cooperation, a joint investment platform established by Norsk Solar, Norfund, and Finnfund.

Heavy duty springs take on the truck industry

Heavy loads put additional pressure on vehicle suspension. This can cause a range of issues, such as reduced brake efficiency, tyre wear and difficulty in steering. It also leads to additional costs, which we have hugely reduced thanks to our new Lesjöfors suspension spring design.The life of a pick-up truck is tough. They mean business, no nonsense, no fuss, just robust handling in rugged terrains. However, look a little deeper and beneath its macho shell is an art of engineering bespoke designed to handle the rough and tumble expectations of a pick-up. There is also a demand for an

There are no items matching the current filter
There are no more items matching the current filter
Back to top